GYX.F FUTURA MEDICAL LS-002

Healthcare Biotechnology Frankfurt Exchange
0.0005 EUR
Close of Nov 12, 2026
0.0005 0.0330
Market cap
EUR 741K
P/E
-
P/B
0.31x
ROE
-323.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is GYX.F undervalued?

Graham number

The Graham number of FUTURA MEDICAL LS-002 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

FUTURA MEDICAL LS-002 fundamental analysis

No fundamental analysis for FUTURA MEDICAL LS-002 yet.

FUTURA MEDICAL LS-002 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About FUTURA MEDICAL LS-002

Futura Medical plc research, develops, and commercializes pharmaceutical and healthcare products for sexual health. The company's lead product includes Eroxon, a topical treatment for erectile dysfunction. It also develops WSD4000 for the treatment of sexual dysfunction in women. The company operates in the United Kingdom, the European Union, the United States, and internationally. Futura Medical plc was incorporated in 2001 and is headquartered in Guildford, the United King…

Full company profile